Literature DB >> 1510386

Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease?

E C Hirsch1.   

Abstract

Although the cause of neuronal death in Parkinson's disease remains unknown, a hyperoxidation phenomenon has been implicated as a potential cytotoxic mechanism. Catecholaminergic neurons containing neuromelanin, an autoxidation byproduct of catecholamines, are more vulnerable in Parkinson's disease than nonmelanized catecholaminergic neurons. High levels of CuZn superoxide dismutase mRNA have been observed in the substantia nigra, suggesting that high levels of oxygen free radicals are indeed produced in the structure. Catecholaminergic neurons surrounded by a low density of glutathione peroxidase cells are more susceptible to degeneration in Parkinson's disease than those well protected against oxidative stress. The nigral content in iron, a compound that exacerbates the production of free radicals in catecholaminergic neurons, is increased in Parkinson's disease. Altogether these data suggest that hyperoxidation may participate in the selective vulnerability of catecholaminergic neurons in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1510386     DOI: 10.1002/ana.410320715

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  14 in total

Review 1.  Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson's disease.

Authors:  Julie K Andersen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

2.  Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian.

Authors:  C Barcia; V Bautista; A Sánchez-Bahillo; E Fernández-Villalba; B Faucheux; M Poza y Poza; A Fernandez Barreiro; E C Hirsch; M-T Herrero
Journal:  J Neural Transm (Vienna)       Date:  2005-01-24       Impact factor: 3.575

3.  Acute administration of dopaminergic drugs has differential effects on locomotion in larval zebrafish.

Authors:  T D Irons; P E Kelly; D L Hunter; R C Macphail; S Padilla
Journal:  Pharmacol Biochem Behav       Date:  2012-12-28       Impact factor: 3.533

4.  Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism.

Authors:  B J Snow; F J Vingerhoets; J W Langston; J W Tetrud; V Sossi; D B Calne
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

5.  Temperature-induced reversible conformational change in the first 100 residues of alpha-synuclein.

Authors:  Brian C McNulty; Ashutosh Tripathy; Gregory B Young; Lisa M Charlton; Jillian Orans; Gary J Pielak
Journal:  Protein Sci       Date:  2006-02-01       Impact factor: 6.725

6.  Therapeutic vitamin A doses increase the levels of markers of oxidative insult in substantia nigra and decrease locomotory and exploratory activity in rats after acute and chronic supplementation.

Authors:  Marcos Roberto de Oliveira; Roberta Bristot Silvestrin; Tadeu Mello e Souza; José Cláudio Fonseca Moreira
Journal:  Neurochem Res       Date:  2007-08-22       Impact factor: 3.996

Review 7.  Perspectives on MAO-B in aging and neurological disease: where do we go from here?

Authors:  M Jyothi Kumar; Julie K Andersen
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

Review 8.  Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration.

Authors:  P S Vosler; C S Brennan; J Chen
Journal:  Mol Neurobiol       Date:  2008-08-07       Impact factor: 5.590

9.  An immunohistochemical study of the neuronal expression of manganese superoxide dismutase in sporadic amyotrophic lateral sclerosis.

Authors:  M Wakai; K Mokuno; Y Hashizume; K Kato
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

10.  Unique responses to mitochondrial complex I inhibition in tuberoinfundibular dopamine neurons may impart resistance to toxic insult.

Authors:  B Behrouz; R E Drolet; Z A Sayed; K J Lookingland; J L Goudreau
Journal:  Neuroscience       Date:  2007-06-20       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.